Substituted pyrido[2,3-B]pyrazines as IP receptor agonists
The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharma...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | MCKEOWN STEPHEN CARL CHARLTON STEVEN JOHN LEBLANC CATHERINE |
description | The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples. |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US9132127B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US9132127B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US9132127B23</originalsourceid><addsrcrecordid>eNrjZLAKLk0qLsksKS1JTVEoqCzKTMmPNtIx1nWKBXISqzLzUosVEosVPAMUilKTUwtK8osUEtPz8zKLS4p5GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakl8aLClobGRoZG5k5ExEUoACOgukg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Substituted pyrido[2,3-B]pyrazines as IP receptor agonists</title><source>esp@cenet</source><creator>MCKEOWN STEPHEN CARL ; CHARLTON STEVEN JOHN ; LEBLANC CATHERINE</creator><creatorcontrib>MCKEOWN STEPHEN CARL ; CHARLTON STEVEN JOHN ; LEBLANC CATHERINE</creatorcontrib><description>The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2015</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150915&DB=EPODOC&CC=US&NR=9132127B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20150915&DB=EPODOC&CC=US&NR=9132127B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>MCKEOWN STEPHEN CARL</creatorcontrib><creatorcontrib>CHARLTON STEVEN JOHN</creatorcontrib><creatorcontrib>LEBLANC CATHERINE</creatorcontrib><title>Substituted pyrido[2,3-B]pyrazines as IP receptor agonists</title><description>The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2015</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLAKLk0qLsksKS1JTVEoqCzKTMmPNtIx1nWKBXISqzLzUosVEosVPAMUilKTUwtK8osUEtPz8zKLS4p5GFjTEnOKU3mhNDeDgptriLOHbmpBfnxqcUFicmpeakl8aLClobGRoZG5k5ExEUoACOgukg</recordid><startdate>20150915</startdate><enddate>20150915</enddate><creator>MCKEOWN STEPHEN CARL</creator><creator>CHARLTON STEVEN JOHN</creator><creator>LEBLANC CATHERINE</creator><scope>EVB</scope></search><sort><creationdate>20150915</creationdate><title>Substituted pyrido[2,3-B]pyrazines as IP receptor agonists</title><author>MCKEOWN STEPHEN CARL ; CHARLTON STEVEN JOHN ; LEBLANC CATHERINE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US9132127B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2015</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>MCKEOWN STEPHEN CARL</creatorcontrib><creatorcontrib>CHARLTON STEVEN JOHN</creatorcontrib><creatorcontrib>LEBLANC CATHERINE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>MCKEOWN STEPHEN CARL</au><au>CHARLTON STEVEN JOHN</au><au>LEBLANC CATHERINE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Substituted pyrido[2,3-B]pyrazines as IP receptor agonists</title><date>2015-09-15</date><risdate>2015</risdate><abstract>The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_epo_espacenet_US9132127B2 |
source | esp@cenet |
subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
title | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A43%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=MCKEOWN%20STEPHEN%20CARL&rft.date=2015-09-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS9132127B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |